Table 5.

Modification by CV disease of the associations of anti-HTN class and number used with mobility impairment, stratified by antiHTN class and number used, respectively ^a

AntiHTN	Mobility Impairment b Adjusted OR (95%CI) c		P-Value for Interaction
	No CV Disease d	Have CV Disease e
Class f
Diuretic	1.03 (0.79, 1.35)	1.40 (0.94, 2.07)	.192
ACEi or ARB	0.86 (0.66, 1.13)	1.23 (0.82, 1.83)	.220
CCB	0.96 (0.72, 1.29)	0.97 (0.65, 1.45)	.995
BB	1.20 (0.92, 1.57)	1.23 (0.84, 1.82)	.981
Number used g
One	0.96 (0.68, 1.36)	2.00 (0.95, 4.21)	.147
Two	0.70 (0.48, 1.02)	1.46 (0.70, 3.03)	.140
Three or more	1.14 (0.77, 1.68)	2.64 (1.28, 5.44)	.077

Abbreviations: ACEi, angiotensin converting enzyme; AntiHTN, antihypertensive; ARB, angiotensin receptor blocker; BB, beta blocker; CCB, calcium channel blocker; BMI, body mass index; CI, confidence interval; CV, cardiovascular; OR, Odds Ratio; SPPB, Short Physical Performance Battery.

^aBecause some characteristics had >5% missing data, multiple imputation was applied (see Statistical Analysis section).

^bSPPB total score ≤7 (moderate-to-severe).

^cAdjusted for age, female gender, non-white race, obesity (BMI ≥30), never-smoker, comorbidities (except CV disease), and non-antiHTN medications.

^dAbsence of established CV disease was defined by not having any of the following: self-reported, physician-diagnosed MI, HF, stroke, or PAD, or adjudicated silent MI on electrocardiogram.

^ePresence of established CV disease was defined by having any of the following: self-reported, physician-diagnosed MI, HF, stroke, or PAD, or adjudicated silent MI on electrocardiogram.

^fComparisons were between medication regimens that included a specified antiHTN class (e.g. diuretic) vs. medication regimens that did not include the specified antiHTN class (e.g. diuretic).

^gComparison is use of one, two, or three or more antiHTN medications vs. no antiHTN medication, respectively.